The US Association for Accessible Medicines has published a position paper urging the US Food and Drug Administration to “revisit and potentially reassess” its safety limits for nitrosamines in pharmaceuticals, while also proposing a “science-driven” risk-based approach to evaluate drugs for the potential presence of nitrosamines.
Nitrosamines – categorized as “high potency mutagenic carcinogens” by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for...




